Toward Using National Cancer Surveillance Data for Preventing and Controlling Cervical and Other Human Papillomavirus-associated Cancers in the US

Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia 30341, USA.
Cancer (Impact Factor: 4.89). 11/2008; 113(10 Suppl):2837-40. DOI: 10.1002/cncr.23753
Source: PubMed


This supplement, known as the ABHACUS (Assessing the Burden of HPV-Associated Cancers in the United States) supplement, contains 22 articles. Together, these articles provide a comprehensive snapshot of data related to the occurrence and control of multiple cancers that have been associated with the human papillomavirus (HPV). These analyses highlight the burden of HPV associated cancers in the US population as a whole and among vulnerable population subgroups. We anticipate that these findings will be an important resource for enhancing existing strategies for the prevention and control of HPV associated cancers.
HPV is estimated to be responsible for 5.2% of the cancers diagnosed worldwide.1 Virtually 100% of cervical cancers are causally associated with HPV, and there is increasing evidence of the role that HPV plays in other anogenital cancers and oropharyngeal cancers. With the recent approval and recommendation of an HPV vaccine that contains HPV–16 and HPV–18, interest in quantifying the spectrum and burden of cancers is heightened. The International Agency for Research on Cancer (IARC) has determined that there is sufficient evidence for the carcinogenicity of HPV–16 in the cervix, vulva, vagina, penis, anus, oral cavity, and oropharynx.2 The IARC has found sufficient evidence of the role HPV–18 plays in cervical cancer, with limited or no evidence in other sites. Together, cervical cancer combined with the other HPV-associated cancers potentially afflicts an additional 25,000 persons every year in the US.
Worldwide and in the US, the excitement and concern surrounding the HPV vaccine has been profound. The excitement derives from the potential of the vaccine to reduce the burden of cervical cancer in countries that have no screening infrastructure as well as in countries such as the US, in which nearly 11,000 women each year are told they have invasive cervical cancer and 4000 die from this disease, despite the availability of screening. The HPV vaccine also has the potential to impact a significant proportion of other cancers for which there typically is no routine screening. Conversely, the concern is that vaccine recipients may not continue to undergo screening for cervical cancer. Yet another concern is that if vaccine uptake is lower in those groups at highest risk of developing cervical cancer, current racial/ethnic or geographic disparities could increase. We hope that the articles in this supplement will highlight the burden and disparities associated with these cancers before vaccine implementation.
This supplement includes an in-depth analysis of cancer incidence and mortality data from population- based central cancer registries that house highquality data. Fourteen articles are based mainly on cancer occurrence, using incidence data from population- based central cancer registries that participate in the Centers for Disease Control and Prevention (CDC)’s National Program of Cancer Registries (NPCR) and/or the National Cancer Institute (NCI)’s Surveillance, Epidemiology, and End Results (SEER) program. The NPCR program, which was established through the Cancer Registries Amendment Act passed by the US Congress in 1992, began providing financial support and technical assistance to population- based central cancer registries in 1994. This program currently supports central registries in 45 states, the District of Columbia, and 3 US territories; these registries cover approximately 96% of the US population. The SEER program, which was established as a result of the National Cancer Act of 1971, currently supports 14 such registries and 3 supplemental registries, covering approximately 26% of the US population. The population-based central cancer registries collect information on all reportable cancer cases within a state or another defined geographic area. Today, the NPCR and SEER programs together cover 100% of the US population, and data regarding more than 1 million new invasive cancer cases are added each year. Medical records are the primary source of the data. Both the NPCR and SEER data are collected and reported with the use of uniform data items and codes, as documented by the North American Association of Central Cancer Registries.3 The Institute of Medicine has recognized the importance of these 2 programs as valuable resources for studies on cancer.4

Download full-text


Available from: Mary C White, Sep 19, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: A medical "registry" is a systematic collection of information from cases of a particular disease or other health relevant condition. Hospital-based registries primarily address prognosis, whereas population-based registries provide estimates of disease incidence. Opportunities to establish and investigate dermatology hospital- and population-based registries abound.
    Dermatologic clinics 05/2009; 27(2):185-91, vii. DOI:10.1016/j.det.2008.11.004 · 1.69 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: From 1975 to the mid 1990s, the incidence of cancer in the oral cavity and pharynx (OC/P) declined substantively, in large part because of successful educational and medical campaigns to reduce cigarette smoking and tobacco chewing. Recent data, however, suggest that the incidence trend in young adults has reversed. The current study investigated National Cancer Institute Surveillance, Epidemiology and End Results databases for changes in the incidence of and survival from OC/P cancer. Since the mid 1990s, females in the United States, between 10 and 40 years of age, have had a steady, apparently accelerating, increase in the incidence of these cancers, particularly in females 15-34 years of age. Most of the increase occurred in the salivary glands and tongue, and were of squamous, acinar, and mucoepidermoid morphologic types. All racial/ethnic groups evaluated have shown the incidence trend pattern, with the increase most prominent in non-Hispanic whites. Five-year survival rates for females 15-39 years of age, when diagnosed to have OC/P cancer, show no improvement since 1975. In contrast, older females and males of all ages continue to demonstrate a reduction in incidence and improvement in survival. The observed patterns are consistent with changing sexual mores and increasing orogenital sexual practices in the United States, with transmission of human papillomavirus and potentially other sexually transmitted carcinogenic vectors. If so, the human papillomavirus vaccines will have cancer prevention benefits beyond cervical carcinoma and will be needed increasingly as the incidence of head and neck cancer is projected to continue to rise in young women.
    Seminars in Oncology 10/2009; 36(5):451-9. DOI:10.1053/j.seminoncol.2009.07.005 · 3.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We performed a retrospective cohort study in a largely Latino population in Los Angeles, surveying 95 parents of 11-17 year old girls between May and June 2008 to examine factors associated with [1] parental consent for Human Papillomavirus (HPV) immunization one year after vaccine implementation and [2] parental support of an HPV vaccine mandate for adolescents prior to middle school entry. 73% of participants had heard of the HPV vaccine and 37% of daughters had already received the vaccine. Variables associated with vaccination included Latino ethnicity, the belief that vaccines are safe, and that HPV vaccine prevents cervical cancer. The most frequent reasons for refusing vaccination included parental request for more information and missed opportunities in clinic. Variables associated with parents agreeing with a law mandating HPV vaccination included: belief in vaccine safety, recent maternal Pap Smear, HPV vaccination of participant's daughter prior to survey, and Latino ethnicity. Our survey supports the work of previous studies recommending continued educational campaigns emphasizing the safety of HPV vaccine, and its efficacy in reducing cervical cancer.
    Vaccine 06/2010; 28(25):4186-91. DOI:10.1016/j.vaccine.2010.04.010 · 3.62 Impact Factor
Show more